Tag: flow diverters

in silico clinical trials

BRAIN 2021: In silico clinical trials likely to play complementary role...

In silico studies involving virtual participants hold great potential in the neurovascular field—and the broader medical industry—with their future role in the generation of...
Diversion-p64 study

Large prospective study demonstrates high efficacy and low mortality rates with...

The Diversion-p64 study—the largest prospective study using the p64 flow modulation device (phenox) to date—has demonstrated that the device has a high level of...

Evasc Neurovascular announces new generation of eClips bifurcation flow diverter

Evasc Neurovascular has announced the third generation of the eClips device. The device is innovated for more effective treatment of intracranial bifurcation aneurysms, facilitating...
coating study phenox

ESMINT 2021: COATING study “badly needed” to assess surface modification of...

This year’s Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT 2021; 8–10 September, Nice, France and virtual) saw details of the...
flow diverter devices

“Welcome and exciting”: Evidence mounts in favour of flow diversion technologies

Multiple pieces of clinical research supporting the use of flow diverter devices to treat intracranial aneurysms have come to light so far in 2021....